The Italian Competition Authority establishes an anticompetitive agreement in the market for ophthalmic drugs used to treat vascular eyesight diseases (Roche / Novartis)

Italian Competition Authority imposes hefty fines on Roche and Novartis* On 27 February 2014, the Italian Competition Authority (“ICA”) issued a decision (in Italian only) finding that Roche and Novartis entered into an anticompetitive agreement in the market for ophthalmic drugs used to treat some serious vascular eyesight conditions, including age-related macular degeneration (“AMD”, which is the main cause of blindness in developed countries) in breach of article 101 of the Treaty on the Functioning of the European Union (“TFEU”) (see Newsletter 1/2013, p.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Gabriele Accardo, The Italian Competition Authority establishes an anticompetitive agreement in the market for ophthalmic drugs used to treat vascular eyesight diseases (Roche / Novartis), 27 February 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 66857

Visites 198

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues